Home.md
... ...
@@ -12,6 +12,7 @@ of mutations in each gene can be found through the gene lists (below). Additiona
12 12
| MCL | [(24 genes)](tier1_mcl) |[(29 genes)](tier2_mcl) |
13 13
14 14
## Origins of B-cell lymphoma gene lists
15
+
15 16
```mermaid
16 17
---
17 18
config:
... ...
@@ -23,128 +24,132 @@ config:
23 24
nodeAlignment: right
24 25
---
25 26
sankey-beta
27
+
26 28
Sanger, 2001, 4
27
-2001, pasqualucci 2001, 4
28
-pasqualucci 2001, DLBCL Tier 1, 3
29
-pasqualucci 2001, DLBCL Tier 2, 1
30
-
31
-RNA-seq/exome, 2011, 49
32
-2011, morin 2011, 25
33
-morin 2011, DLBCL Tier 1, 25
34
-2011, morin 2011, 15
35
-morin 2011, FL Tier 2, 1
36
-morin 2011, FL Tier 1, 14
37
-2011, pasqualucci 2011a, 7
38
-pasqualucci 2011a, DLBCL Tier 1, 5
39
-pasqualucci 2011a, DLBCL Tier 2, 2
40
-2011, pasqualucci 2011b, 2
41
-pasqualucci 2011b, FL Tier 1, 2
42
-pasqualucci 2011b, DLBCL Tier 1, 2
43
-
44
-exome, 2012-exome, 68
45
-2012-exome, richter 2012, 5
46
-2012-exome, lohr 2012, 4
47
-2012-exome, love 2012, 59
48
-
49
-richter 2012, BL Tier 1, 5
50
-lohr 2012, DLBCL Tier 2, 1
51
-lohr 2012, DLBCL Tier 1, 3
52
-love 2012, BL Tier 1, 3
53
-love 2012, BL Tier 2, 56
54
-
55
-RNA-seq, 2012-RNA-seq, 19
56
-2012-RNA-seq, schmitz 2012, 19
57
-schmitz 2012, BL Tier 1, 3
58
-schmitz 2012, BL Tier 2, 16
59
-
60
-WGS, 2013-WGS, 40
61
-2013-WGS, morin 2013, 40
62
-morin 2013, DLBCL Tier 2, 29
63
-morin 2013, DLBCL Tier 1, 11
64
-
65
-exome, 2013-exome, 19
66
-2013-exome, zhang 2013, 19
67
-zhang 2013, DLBCL Tier 1, 11
68
-zhang 2013, DLBCL Tier 2, 8
69
-
70
-exome, 2014-exome, 3
71
-2014-exome, muppidi 2014, 3
72
-muppidi 2014, BL Tier 1, 1
73
-muppidi 2014, BL Tier 2, 2
74
-
75
-exome, 2016-exome, 2
76
-2016-exome, mareschal 2016, 2
77
-mareschal 2016, DLBCL Tier 1, 2
78
-
79
-WGS, 2016-WGS, 2
80
-2016-WGS, okosun 2016, 2
81
-okosun 2016, FL Tier 1, 2
82
-
83
-exome, 2016-exome, 2
84
-2016-exome, morin 2016, 2
85
-morin 2016, DLBCL Tier 1, 2
86
-
87
-exome, 2017-exome, 85
88
-2017-exome, krysiak 2017, 22
89
-krysiak 2017, FL Tier 2, 5
90
-krysiak 2017, FL Tier 1, 17
91
-
92
-2017-exome, albuquerque 2017, 3
93
-albuquerque 2017, DLBCL Tier 1, 3
94
-
95
-2017-exome, reddy 2017, 60
96
-reddy 2017, DLBCL Tier 2, 50
97
-reddy 2017, DLBCL Tier 1, 10
98
-
99
-exome, 2018-exome, 35
100
-2018-exome, schmitz 2018, 16
101
-schmitz 2018, DLBCL Tier 2, 7
102
-schmitz 2018, DLBCL Tier 1, 9
103
-
104
-2018-exome, chapuy 2018, 19
105
-chapuy 2018, DLBCL Tier 2, 16
106
-chapuy 2018, DLBCL Tier 1, 3
107
-
108
-WGS, 2018-WGS, 20
109
-2018-WGS, arthur 2018, 20
110
-arthur 2018, DLBCL Tier 2, 12
111
-arthur 2018, DLBCL Tier 1, 8
112
-
113
-RNA-seq/exome,2019-RNA-seq/exome,47
114
-2019-RNA-seq/exome, panea 2019, 47
115
-panea 2019, BL Tier 2, 43
116
-panea 2019, BL Tier 1, 4
117
-
118
-WGS,2019-WGS,13
119
-2019-WGS, grande 2019, 13
120
-grande 2019, BL Tier 1, 8
121
-grande 2019, BL Tier 2, 5
122
-
123
-exome, 2020-exome, 2
124
-2020-exome, pararajalingam 2020, 2
125
-pararajalingam 2020, DLBCL Tier 1, 2
126
-
127
-WGS, 2021-WGS, 40
128
-2021-WGS, hubschmann 2021, 17
129
-2021-WGS, hubschmann 2021, 23
130
-hubschmann 2021, FL Tier 2, 15
131
-hubschmann 2021, FL Tier 1, 2
132
-hubschmann 2021, DLBCL Tier 1, 4
133
-hubschmann 2021, DLBCL Tier 2, 19
134
-
135
-exome, 2023-exome, 20
136
-2023-exome, russler 2023, 20
137
-russler 2023, FL Tier 1, 1
138
-russler 2023, FL Tier 2, 19
139
-
140
-Panel, 2022-panel, 25
141
-2022-panel, burkhardt 2022, 25
142
-burkhardt 2022, BL Tier 2, 25
143
-
144
-WGS, 2023-WGS, 3
145
-2023-WGS, thomas 2023, 3
146
-thomas 2023, BL Tier 2, 1
147
-thomas 2023, BL Tier 1, 2
29
+2001, Pasqualucci 2001, 4
30
+Pasqualucci 2001, DLBCL Tier 1, 3
31
+Pasqualucci 2001, DLBCL Tier 2, 1
32
+
33
+RNA-seq/WGS, 2011, 49
34
+2011, Morin 2011, 25
35
+Morin 2011, DLBCL Tier 1, 25
36
+2011, Morin 2011, 15
37
+Morin 2011, FL Tier 1, 14
38
+Morin 2011, FL Tier 2, 1
39
+2011, Pasqualucci 2011a, 7
40
+Pasqualucci 2011a, DLBCL Tier 1, 5
41
+Pasqualucci 2011a, DLBCL Tier 2, 2
42
+2011, Pasqualucci 2011b, 2
43
+Pasqualucci 2011b, FL Tier 1, 2
44
+Pasqualucci 2011b, DLBCL Tier 1, 2
45
+
46
+exome, 2012 exome studies, 68
47
+2012 exome studies, Richter 2012, 5
48
+2012 exome studies, Lohr 2012, 4
49
+2012 exome studies, Love 2012, 59
50
+
51
+Richter 2012, BL Tier 1, 5
52
+Lohr 2012, DLBCL Tier 1, 3
53
+Lohr 2012, DLBCL Tier 2, 1
54
+Love 2012, BL Tier 1, 3
55
+Love 2012, BL Tier 2, 56
56
+
57
+RNA-seq, 2012 RNA-seq studies, 19
58
+2012 RNA-seq studies, Schmitz 2012, 19
59
+Schmitz 2012, BL Tier 1, 3
60
+Schmitz 2012, BL Tier 2, 16
61
+
62
+WGS, 2013 WGS studies, 40
63
+2013 WGS studies, Morin 2013, 40
64
+Morin 2013, DLBCL Tier 1, 11
65
+Morin 2013, DLBCL Tier 2, 29
66
+
67
+
68
+exome, 2013 exome studies, 19
69
+2013 exome studies, Zhang 2013, 19
70
+Zhang 2013, DLBCL Tier 1, 11
71
+Zhang 2013, DLBCL Tier 2, 8
72
+
73
+exome, 2014 exome studies, 3
74
+2014 exome studies, Muppidi 2014, 3
75
+Muppidi 2014, BL Tier 1, 1
76
+Muppidi 2014, BL Tier 2, 2
77
+
78
+exome, 2016 exome studies, 2
79
+2016 exome studies, Mareschal 2016, 2
80
+Mareschal 2016, DLBCL Tier 1, 2
81
+
82
+WGS, 2016 WGS studies, 2
83
+2016 WGS studies, Okosun 2016, 2
84
+Okosun 2016, FL Tier 1, 2
85
+
86
+exome, 2016 exome studies, 2
87
+2016 exome studies, Morin 2016, 2
88
+Morin 2016, DLBCL Tier 1, 2
89
+
90
+exome, 2017 exome studies, 85
91
+2017 exome studies, Krysiak 2017, 22
92
+Krysiak 2017, FL Tier 1, 17
93
+Krysiak 2017, FL Tier 2, 5
94
+
95
+
96
+2017 exome studies, Albuquerque 2017, 3
97
+Albuquerque 2017, DLBCL Tier 1, 3
98
+
99
+2017 exome studies, Reddy 2017, 60
100
+Reddy 2017, DLBCL Tier 2, 50
101
+Reddy 2017, DLBCL Tier 1, 10
102
+
103
+exome, 2018 exome studies, 35
104
+2018 exome studies, Schmitz 2018, 16
105
+Schmitz 2018, DLBCL Tier 2, 7
106
+Schmitz 2018, DLBCL Tier 1, 9
107
+
108
+2018 exome studies, Chapuy 2018, 19
109
+Chapuy 2018, DLBCL Tier 2, 16
110
+Chapuy 2018, DLBCL Tier 1, 3
111
+
112
+WGS, 2018 WGS studies, 20
113
+2018 WGS studies, Arthur 2018, 20
114
+Arthur 2018, DLBCL Tier 2, 12
115
+Arthur 2018, DLBCL Tier 1, 8
116
+
117
+RNA-seq/exome,2019 RNA-seq/exome studies,47
118
+2019 RNA-seq/exome studies, Panea 2019, 47
119
+Panea 2019, BL Tier 2, 43
120
+Panea 2019, BL Tier 1, 4
121
+
122
+WGS,2019 WGS studies,13
123
+2019 WGS studies, Grande 2019, 13
124
+Grande 2019, BL Tier 1, 8
125
+Grande 2019, BL Tier 2, 5
126
+
127
+exome, 2020 exome studies, 2
128
+2020 exome studies, Pararajalingam 2020, 2
129
+Pararajalingam 2020, DLBCL Tier 1, 2
130
+
131
+WGS, 2021 WGS studies, 40
132
+2021 WGS studies, Hubschmann 2021, 17
133
+2021 WGS studies, Hubschmann 2021, 23
134
+Hubschmann 2021, FL Tier 2, 15
135
+Hubschmann 2021, FL Tier 1, 2
136
+Hubschmann 2021, DLBCL Tier 1, 4
137
+Hubschmann 2021, DLBCL Tier 2, 19
138
+
139
+exome, 2023 exome studies, 20
140
+2023 exome studies, Russler-Germain 2023, 20
141
+Russler-Germain 2023, FL Tier 1, 1
142
+Russler-Germain 2023, FL Tier 2, 19
143
+
144
+Panel, panel studies, 25
145
+panel studies, Burkhardt 2022, 25
146
+Burkhardt 2022, BL Tier 2, 25
147
+
148
+WGS, 2023 WGS studies, 3
149
+2023 WGS studies, Thomas 2023, 3
150
+Thomas 2023, BL Tier 2, 1
151
+Thomas 2023, BL Tier 1, 2
152
+
148 153
```
149 154
150 155
## B-cell Lymphoma aSHM targets